Get the Stockscreener App
5.07
0.80%
0.04
Pre-market:
5.01
-0.06
-1.18%
Aldeyra Therapeutics Inc stock is traded at $5.07, with a volume of 568.77K.
It is up +0.80% in the last 24 hours and down -2.87% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$5.03
Open:
$5.01
24h Volume:
568.77K
Relative Volume:
0.74
Market Cap:
$303.67M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-6.76
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
-3.24%
1M Performance:
-2.87%
6M Performance:
+91.32%
1Y Performance:
-3.61%
1-Day Range:
$4.85
$5.11
1-Week Range:
$4.696
$5.40
52-Week Range:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.07 | 302.03M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Can a trend reversal in Aldeyra Therapeutics Inc. lead to recovery2025 Risk Factors & AI Based Trade Execution Alerts - newser.com
Intraday pattern recognizer results for Aldeyra Therapeutics Inc.2025 Top Decliners & Growth Focused Stock Reports - newser.com
Sentiment analysis tools applied to Aldeyra Therapeutics Inc.July 2025 Patterns & Technical Confirmation Trade Alerts - newser.com
Live market analysis of Aldeyra Therapeutics Inc.2025 Price Momentum & Short-Term Swing Trade Alerts - newser.com
Will Aldeyra Therapeutics Inc. stock split again soonShort Setup & Smart Money Movement Alerts - newser.com
Why Aldeyra Therapeutics Inc. stock could see breakout soonJuly 2025 Market Mood & Breakout Confirmation Alerts - newser.com
Why analysts upgrade Aldeyra Therapeutics Inc. stockJuly 2025 Outlook & Stepwise Entry/Exit Trade Alerts - newser.com
Combining price and volume data for Aldeyra Therapeutics Inc.Stock Surge & Safe Capital Allocation Plans - newser.com
Is Aldeyra Therapeutics Inc. stock attractive for ETFsIndex Update & Weekly High Momentum Picks - newser.com
How to interpret RSI for Aldeyra Therapeutics Inc. stockMarket Risk Report & Weekly High Return Stock Opportunities - newser.com
Aldeyra Therapeutics Inc.’s volatility index tracking explainedWeekly Trade Analysis & Consistent Growth Stock Picks - newser.com
Is Aldeyra Therapeutics Inc. stock resilient to inflation2025 Retail Activity & Reliable Volume Spike Trade Alerts - newser.com
Analyzing net buyer seller activity in Aldeyra Therapeutics Inc.Portfolio Gains Report & Risk Managed Investment Strategies - newser.com
What insider trading reveals about Aldeyra Therapeutics Inc. stock2025 Momentum Check & High Win Rate Trade Alerts - newser.com
Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success - Indian Pharma Post
Is Aldeyra Therapeutics Inc. stock dividend yield sustainableJuly 2025 Review & AI Enhanced Trade Execution Alerts - newser.com
Catalyst Monitor Outlook, Q4 2025 Report: Pipeline Advances with Key Approvals and Trials: Featuring Cytokinetics's Aficamten, Aldeyra's Reproxalap, GSK's Depemokimab - Yahoo Finance
Evaluating Aldeyra Therapeutics Inc. with trendline analysisWeekly Profit Analysis & Daily Chart Pattern Signal Reports - newser.com
Is Aldeyra Therapeutics Inc. stock affected by interest rate hikesStock Surge & Low Drawdown Momentum Ideas - newser.com
Aldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Aldeyra’s Experimental Drug Shows Promising Results In Mid-Stage Alcohol Hepatitis Trial - MSN
Aldeyra Cans RASP Asset, Brings Forward Two Others in Pipeline Shakeup - BioSpace
Aldeyra reshuffles pipeline, culling asset despite Phase II success - Yahoo Finance
Aldeyra reports positive liver function results for ADX-629 in trial - Investing.com Australia
Three Boston biotechs await FDA decisions on new drugs by year-end - The Business Journals
What candlestick patterns are forming on Aldeyra Therapeutics Inc.Day Trade & Community Consensus Trade Alerts - newser.com
Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development - Stocktwits
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):